Lymphoma, B-Cell, Marginal Zone - 24 Studies Found
| Not yet recruiting |
: Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma : Splenic Marginal Zone Lymphoma : 2016-10-23 |
| Not yet recruiting |
: Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type : MALT Lymphoma : 2009-06-17 : Drug: Lenalidomide 25 mg Lenalidomide p.o. daily for 21 days |
| Completed |
: Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients : MALT Lymphoma : 2006-09-07 : Drug: Thalidomide, Pharmion 200 mg p.o. daily |
| Active, not recruiting |
: R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML) : Lymphoma : 2011-08-30 : Drug: rituximab, cyclophosphamide, vincristine, and prednisolone 6 cycles of R-CVP followed by 2 cycles |